HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this link to a friend Similar articles in this journal Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Tornillo, L Articles by Terracciano, L M Search for Related Content PubMed PubMed Citation Articles by Tornillo, L Articles by Terracciano, L M

An update on molecular genetics of gastrointestinal stromal tumours

Institute of Pathology, University of Basel, Basel, Switzerland

Correspondence to:
Dr Luigi Tornillo
Institute of Pathology, University of Basel, Schönbeinstrasse 40, CH-4003 Basel, Switzerland; tornillol{at}uhbs.ch
ABSTRACT
Gastrointestinal stromal tumours (GISTs) are the most common primary mesenchymal tumours of the gastrointestinal tract. Most of them show activating mutations of the genes coding for KIT or platelet-derived growth factor receptor (PDGFR), two receptor tyrosine kinases (RTKs). The RTK inhibitor Imatinib (Gleevec®, Novartis, Switzerland), induces regression of the tumour. The level of response to treatment, together with other clinicopathological parameters is related to the type and site of the activating mutation, thus suggesting that these tumours should be classified according to the molecular context. This is confirmed also by the phenomenon of the resistance to treatment, which arises because of different mechanisms (second mutation, amplification, activation of other RTKs) and can be fought only by specific RTK inhibitors, that are at present under development. RTK activation involves an homogeneous transduction pathway whose components (MAPK, AKT, PI3K, mTOR and RAS) are possible targets of new molecular treatment. A new paradigm of classification integrating the classic pathological criteria with the molecular changes will permit personalised prognosis and treatment.

Abbreviations: GIST, gastrointestinal stromal tumours; ICC, interstitial cells of Cajal; PDGFR, Platelet-derived growth factor receptor; PI3K, phosphatidylinositol-3-kinase; RTK, receptor tyrosine kinases

This article has been cited by other articles:

				C. Braconi, R. Bracci, I. Bearzi, F. Bianchi, A. Costagliola, R. Catalani, A. Mandolesi, R. Ranaldi, E. Galizia, S. Cascinu, et al. KIT and PDGFR{alpha} mutations in 104 patients with gastrointestinal stromal tumors (GISTs): a population-based study Ann. Onc., April 1, 2008; 19(4): 706 - 710. [Abstract] [Full Text] [PDF]

				A L Gomes, A Gouveia, A F Capelinha, D de la Cruz, P Silva, R M Reis, A Pimenta, and J M Lopes Molecular alterations of KIT and PDGFRA in GISTs: evaluation of a Portuguese series J. Clin. Pathol., February 1, 2008; 61(2): 203 - 208. [Abstract] [Full Text] [PDF]

				F.=C> Miselli, P. Casieri, T. Negri, M. Orsenigo, M. S. Lagonigro, A. Gronchi, M. Fiore, P. G. Casali, R. Bertulli, A. Carbone, et al. c-Kit/PDGFRA Gene Status Alterations Possibly Related to Primary Imatinib Resistance in Gastrointestinal Stromal Tumors Clin. Cancer Res., April 15, 2007; 13(8): 2369 - 2377. [Abstract] [Full Text] [PDF]